Similarly, the beneficial effect of early initiation of β-blocker and mineralocorticoid receptor antagonist in a setting of acute MI complicated by reduced left ventricular ejection fraction has also been established in pivotal clinical studies, such as the CAPRICORN (Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction) and EPHESUS (Eplerenone Post-AMI Heart Failure Efficacy and Survival Study) trials [35,36]. Here, NR3C2 is linked to heart failure.